Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mathematical models of breast and ovarian cancers.
Botesteanu DA, Lipkowitz S, Lee JM, Levy D. Botesteanu DA, et al. Among authors: lipkowitz s. Wiley Interdiscip Rev Syst Biol Med. 2016 Jul;8(4):337-62. doi: 10.1002/wsbm.1343. Epub 2016 Jun 3. Wiley Interdiscip Rev Syst Biol Med. 2016. PMID: 27259061 Free PMC article. Review.
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC. Lee JM, et al. Among authors: lipkowitz s. J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4. J Clin Oncol. 2017. PMID: 28471727 Free PMC article. Clinical Trial.
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC. Lee JM, et al. Among authors: lipkowitz s. Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108297 Free PMC article.
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC. Lee JM, et al. Among authors: lipkowitz s. Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18. Lancet Oncol. 2018. PMID: 29361470 Free PMC article.
Update on PARP Inhibitors in Breast Cancer.
Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Zimmer AS, et al. Among authors: lipkowitz s. Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2. Curr Treat Options Oncol. 2018. PMID: 29644491 Free PMC article. Review.
First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.
Kurdziel KA, Mena E, McKinney Y, Wong K, Adler S, Sissung T, Lee J, Lipkowitz S, Lindenberg L, Turkbey B, Kummar S, Milenic DE, Doroshow JH, Figg WD, Merino MJ, Paik CH, Brechbiel MW, Choyke PL. Kurdziel KA, et al. Among authors: lipkowitz s. J Transl Sci. 2019 Apr;5(2):10.15761/JTS.1000269. doi: 10.15761/JTS.1000269. Epub 2018 Jul 13. J Transl Sci. 2019. PMID: 30906574 Free PMC article.
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM. Zimmer AS, et al. Among authors: lipkowitz s. J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3. J Immunother Cancer. 2019. PMID: 31345267 Free PMC article. Clinical Trial.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Lampert EJ, et al. Among authors: lipkowitz s. Clin Cancer Res. 2020 Aug 15;26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. Epub 2020 May 12. Clin Cancer Res. 2020. PMID: 32398324 Free PMC article. Clinical Trial.
A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.
Gatti-Mays ME, Karzai FH, Soltani SN, Zimmer A, Green JE, Lee MJ, Trepel JB, Yuno A, Lipkowitz S, Nair J, McCoy A, Lee JM. Gatti-Mays ME, et al. Among authors: lipkowitz s. Oncologist. 2020 Dec;25(12):1013-e1824. doi: 10.1634/theoncologist.2020-0491. Epub 2020 Jun 24. Oncologist. 2020. PMID: 32510664 Free PMC article. Clinical Trial.
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.
Green DS, Ning F, Duemler A, Myers TG, Trewhitt K, Ekwede I, McCoy A, Houston N, Lee JM, Lipkowitz S, Zimmer A, Pavelova M, Villanueva EN, Smith L, Blakely A, Casablanca Y, Highfill SL, Stroncek DF, Collins-Johnson N, Panch S, Procter J, Pham C, Korrapati S, Holland SM, Rosen LB, Nunes AT, Zoon KC, Cole CB, Annunziata CM. Green DS, et al. Among authors: lipkowitz s. Clin Cancer Res. 2023 Jan 17;29(2):349-363. doi: 10.1158/1078-0432.CCR-22-1893. Clin Cancer Res. 2023. PMID: 36099324 Free PMC article. Clinical Trial.
132 results